Myeloproliferative neoplasms (MPNs) carry diverse characters, authors noted in a recent review that sought to understand the complexity of the MPN symptom burden and identify how patient reported outcome (PRO) tools can be used to assess such burden. Risk scores and MPN chronicity do not often relate to symptomatic burden. MPN PROs allow for precise and rapid assessment of the symptom burden and have led to better understanding of how such burden and overall patient experience is impacted by novel and traditional therapies. The authors pointed out that PRO tools are incorporated into National Comprehensive Cancer Center guidelines, and thus should be used to assess disease burden.